HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find → Understand → Decide

Atezolizumab

Discovery priority: LOW · POSSIBLE / INVESTIGATE

Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.

Why investigate?

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN

Biology implicated: UNCLEAR · Failure context: UNKNOWN

MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.

Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN

Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.

Existing buyer gates

Human Signal: UNKNOWN

Cheap Truth: UNKNOWN

Clean Rights: UNKNOWN

Market Pull: UNKNOWN

No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.

Evidence timeline

2026-07-31 · trial:NCT05058651

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

End of Initial Phase of Multi-phase protocol

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "650177106752fa72ed5cb19212e0178f380b0fe1b5318108fe2830196821977a",
  "metadata": {
    "complete": false,
    "content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
    "failed": false,
    "last_checked": 1790026985.182528,
    "last_success": 1790026985.182528,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
  "raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT05058651"
}

2026-09-01 · trial:NCT01810913

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Other - Assessing accrual feasibility

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "392d89a557ce08b908569204607cd7c2e838d4ee8fc6dc34a96de9db01ad1648",
  "metadata": {
    "complete": false,
    "content_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
    "failed": false,
    "last_checked": 1790026984.0751398,
    "last_success": 1790026984.0751398,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
  "raw_path": "research/obz7_sources/38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT01810913"
}

2026-09-14 · trial:NCT04402788

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Scheduled Interim Monitoring

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "5e3f0b4f0f7d392f63b0400636f83be2e2f402294224337e9acbdcc16054e9b8",
  "metadata": {
    "complete": false,
    "content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
    "failed": false,
    "last_checked": 1790026985.182528,
    "last_success": 1790026985.182528,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
  "raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT04402788"
}

2026-09-15 · trial:NCT05908786

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Study was closed early as the sponsor decided not to continue development of certain treatment combinations.

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "1d5266fb285142f60f271b1104652d346c3c7bc5cf6f15d77d58961426ac7b1f",
  "metadata": {
    "complete": false,
    "content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
    "failed": false,
    "last_checked": 1790026980.9308648,
    "last_success": 1790026980.9308648,
    "live_verified": true,
    "scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
  "raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT05908786"
}

2026-09-18 · trial:NCT06616623

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Pending ICF update

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "af59fa582e22abbc220ba618c6c653759567928f70580be9898bdfbedcec845d",
  "metadata": {
    "complete": false,
    "content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
    "failed": false,
    "last_checked": 1790026985.182528,
    "last_success": 1790026985.182528,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
  "raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT06616623"
}

Freshness is claim-specific

Fetching an old filing today does not establish current ownership or program status.

pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:04.075140+00:00

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00

Registry observations (6)

NCT05908786 · TERMINATED · PHASE1, PHASE2 · Carcinoma, Hepatocellular · Trial sponsor Hoffmann-La Roche

Reported aliases: Tecentriq. Identity, treatment role and exposure require review.

NCT01810913 · SUSPENDED · PHASE2, PHASE3 · Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma; Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 · Trial sponsor National Cancer Institute (NCI)

Reported aliases: MPDL 3280A; MPDL 328OA; MPDL-3280A; MPDL3280A; MPDL328OA; RG 7446; RG-7446; RG7446; RO 5541267; RO-5541267; RO5541267; Tecentriq. Identity, treatment role and exposure require review.

NCT06616623 · SUSPENDED · PHASE1 · Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 · Trial sponsor Dwight Owen

Reported aliases: MPDL 3280A; MPDL 328OA; MPDL-3280A; MPDL3280A; MPDL328OA; RG 7446; RG-7446; RG7446; RO 5541267; RO-5541267; RO5541267; Tecentriq. Identity, treatment role and exposure require review.

NCT04402788 · SUSPENDED · PHASE2, PHASE3 · Extensive Stage Lung Small Cell Carcinoma · Trial sponsor National Cancer Institute (NCI)

Reported aliases: MPDL 3280A; MPDL 328OA; MPDL-3280A; MPDL3280A; MPDL328OA; RG 7446; RG-7446; RG7446; RO 5541267; RO-5541267; RO5541267; Tecentriq. Identity, treatment role and exposure require review.

NCT05058651 · SUSPENDED · PHASE2, PHASE3 · Advanced Extrapulmonary Neuroendocrine Carcinoma; Metastatic Extrapulmonary Neuroendocrine Carcinoma; Recurrent Extrapulmonary Neuroendocrine Carcinoma; Unresectable Extrapulmonary Neuroendocrine Carcinoma · Trial sponsor National Cancer Institute (NCI)

Reported aliases: MPDL 3280A; MPDL 328OA; MPDL-3280A; MPDL3280A; MPDL328OA; RG 7446; RG-7446; RG7446; RO 5541267; RO-5541267; RO5541267; Tecentriq. Identity, treatment role and exposure require review.

NCT04665856 · COMPLETED · PHASE3 · Small Cell Lung Carcinoma · Trial sponsor Hoffmann-La Roche

Reported aliases: Tecentriq. Identity, treatment role and exposure require review.

Back to discovery